Retatrutide is currently an investigational medication undergoing Phase 3 clinical trials and is not approved by Health Canada or the FDA for medical use
For mild nausea Try smaller portions and eat slowly
For tirzepatide at the highest dose, the SURMOUNT-1 trial showed an average of 22.5% weight loss at 72 weeks, which represents one of the most significant weight loss results ever achieved with any medication
This is a safe, non-invasive first step for anyone curious about their current health status or looking for a clear baseline before starting any lifestyle or medical intervention
How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test analyzes variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) to reveal predispositions in peptide and metabolic pathways
By following these practical tips, using gentle skincare products, and knowing when to seek medical advice, you can minimize discomfort and maintain healthy skin